{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:02:08Z","timestamp":1789495328611,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010653","name":"Masarykova Univerzita","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejpb.2025.114790","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T19:28:40Z","timestamp":1750447720000},"page":"114790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The impact of ionic excipients on stabilization of enalapril tablets by the formation of alkaline salt \u201cin situ\u201d"],"prefix":"10.1016","volume":"214","author":[{"given":"Ale\u0161","family":"Franc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u0159ek","family":"\u017daludek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Sova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-7831","authenticated-orcid":false,"given":"Roman","family":"Gon\u011bc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3885","authenticated-orcid":false,"given":"Jan","family":"Musel\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114790_b0005","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/03639045.2017.1304960","article-title":"Stability of pharmaceutical salts in solid oral dosage forms","volume":"43","author":"Nie","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2025.114790_b0010","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1021\/acs.cgd.0c01427","article-title":"Advanced methodologies for pharmaceutical salt synthesis","volume":"21","author":"Hossain Mithu","year":"2021","journal-title":"Cryst. Growth & Des."},{"key":"10.1016\/j.ejpb.2025.114790_b0015","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3390\/molecules23071719","article-title":"Salts of therapeutic agents: chemical, physicochemical, and biological considerations","volume":"23","author":"Gupta","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2025.114790_b0020","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.xphs.2017.04.019","article-title":"Biowaiver monographs for immediate-release solid oral dosage forms: Enalapril","volume":"106","author":"Verbeeck","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114790_b0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jps.3030410315","article-title":"A comparative study of tablet disintegrating agents","volume":"41","author":"Gross","year":"1952","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.ejpb.2025.114790_b0030","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/pharmaceutics13091364","article-title":"Structural changes of sodium warfarin in tablets affecting the dissolution profiles and potential safety of generic substitution","volume":"13","author":"Musel\u00edk","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114790_b0035","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10973-021-10596-7","article-title":"Study on the stability and compatibility mechanism of enalapril maleate based on pKa and pH microenvironment","volume":"146","author":"Su","year":"2021","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ejpb.2025.114790_b0040","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10973-007-8187-4","article-title":"Stability and compatibility study on enalapril maleate using thermoanalytical techniques","volume":"93","author":"Rezende","year":"2008","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ejpb.2025.114790_b0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.tca.2011.10.020","article-title":"Synthesis of diketopiperazine: a kinetic study by means of thermoanalytical methods","volume":"527","author":"Lick","year":"2012","journal-title":"Thermochim. Acta"},{"key":"10.1016\/j.ejpb.2025.114790_b0050","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1021\/jm00382a008","article-title":"Angiotensin-converting enzyme inhibitors: synthesis and biological activity of acyltripeptide analogs of enalapril","volume":"28","author":"Greenlee","year":"1985","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114790_b0055","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1590\/S0100-40422011000300016","article-title":"Chemical stability of enalapril maleate drug substance and tablets by a stability-indicating liquid chromatographic method","volume":"34","author":"Diego","year":"2011","journal-title":"Quim Nova"},{"key":"10.1016\/j.ejpb.2025.114790_b0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/01480549709003891","article-title":"First-pass effect: significance of the intestine for absorption and metabolism","volume":"20","author":"Doherty","year":"1997","journal-title":"Drug Chem. Toxicol."},{"key":"10.1016\/j.ejpb.2025.114790_b0065","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2174\/156802611797183285","article-title":"Prodrug strategies for antihypertensives","volume":"11","author":"Dhaneshwar","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114790_b0070","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2478\/v10007-012-0039-5","article-title":"Influence of different types of commercially available microcrystalline cellulose on degradation of perindopril erbumine and enalapril maleate in binary mixtures","volume":"62","author":"Vehovec","year":"2012","journal-title":"Acta Pharm."},{"key":"10.1016\/j.ejpb.2025.114790_b0075","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.xphs.2020.11.037","article-title":"Study on the mechanism responsible for the incompatibility of enalapril maleate with sodium starch glycolate","volume":"110","author":"Bout","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114790_b0080","article-title":"Influence of commonly used excipients on the chemical degradation of enalapril maleate in its solid state: the role of condensed water","volume":"171","author":"Bout","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114790_b0085","unstructured":"W. Fulberth, R. Leeb, M, Radau, W S Stammberger, Stabilized polymer film coated compounds and stabilized formulations in compressed from using same, U.S. Patent 4,442,008 (1987)."},{"key":"10.1016\/j.ejpb.2025.114790_b0090","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.carbpol.2011.05.008","article-title":"Enalapril: \u03b2-CD complex: stability enhancement in solid state","volume":"86","author":"Zoppi","year":"2011","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2025.114790_b0095","unstructured":"K.S. Murthy, M. Harris, G.C. Hokanson, R.G. Reisch, M.B. Fawzi, F. Waldman, Drug compositions stabilized against oxidation, US Patent 4,830,853 (1986)."},{"key":"10.1016\/j.ejpb.2025.114790_b0100","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3109\/10837450.2014.959178","article-title":"Improvement of enalapril maleate chemical stability by high shear melting granulation","volume":"20","author":"de Oliveira","year":"2015","journal-title":"Pharm. Dev. Tech."},{"key":"10.1016\/j.ejpb.2025.114790_b0105","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1208\/s12249-016-0593-0","article-title":"Fluidized bed hot melt granulation with hydrophilic materials improves enalapril maleate stability","volume":"18","author":"Guimar\u00e3es","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2025.114790_b0110","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1208\/s12249-013-0006-6","article-title":"Effect of stearic acid on enalapril stability and dissolution from multiparticulate solid dosage forms","volume":"14","author":"Cunha","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2025.114790_b0115","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1002\/jps.22161","article-title":"Package selection for moisture protection for solid, oral drug products","volume":"99","author":"Waterman","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114790_b0120","first-page":"415","article-title":"Kinetics of degradation of enalapril maleate in dosage forms","volume":"61","author":"Stanisz","year":"2004","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114790_b0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00894-023-05597-2","article-title":"Studies on charge transfer of enalapril maleate: from solid-state to molecular dynamics","volume":"29","author":"Louren\u00e7o","year":"2023","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.ejpb.2025.114790_b0130","article-title":"Stabilized pharmaceutical agents, process for preparing them, and stable pharmaceutical preparations","volume":"0317878","author":"F\u00fclberth","year":"1987","journal-title":"Eur. Patent"},{"key":"10.1016\/j.ejpb.2025.114790_b0135","unstructured":"M. Harris, G. Hokanson, K., Murthy, R. Reisch, F. Waldman, Stabilized compositions, U.S. Patent 4,743,450 (1987)."},{"key":"10.1016\/j.ejpb.2025.114790_b0140","first-page":"277","article-title":"Proposal of a new degradation mechanism of enalapril maleate and improvement of enalapril maleate stability in tablet formulation with different stabilizers","volume":"69","author":"Chen","year":"2014","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2025.114790_b0145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jpba.2008.11.029","article-title":"Stability of new potential ACE inhibitor in the aqueous solutions of different pH","volume":"49","author":"Ro\u0161kar","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2025.114790_b0150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2478\/acph-2014-0022","article-title":"Influence of process parameters on content uniformity of a low dose active pharmaceutical ingredient in a tablet formulation according to GMP","volume":"64","author":"Musel\u00edk","year":"2014","journal-title":"Acta Pharm."},{"key":"10.1016\/j.ejpb.2025.114790_b0155","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1081\/DDC-100102242","article-title":"Search for related substances in market products containing enalapril maleate as the active principle","volume":"25","author":"Pilatti","year":"1999","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2025.114790_b0160","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jpba.2008.02.030","article-title":"Stability and in vitro release profile of enalapril maleate from different commercially available tablets: possible therapeutic implications","volume":"47","author":"Lima","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2025.114790_b0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10837450802244686","article-title":"Preparation and characterization of salt forms of enalapril","volume":"13","author":"Kumar","year":"2008","journal-title":"Pharm. Dev. Tech."},{"key":"10.1016\/j.ejpb.2025.114790_b0170","article-title":"Stable solid formulation of enalapril salt and process for preparation thereof","volume":"1442746","author":"Sherman","year":"1995","journal-title":"Eur. Patent"},{"key":"10.1016\/j.ejpb.2025.114790_b0175","unstructured":"Guideline ICH Q3B (R2), Impurities in new drug products, (2006) 1-5."},{"key":"10.1016\/j.ejpb.2025.114790_b0180","first-page":"4123","article-title":"Solubility and thermodynamics of lithium carbonate in sodium carbonate solution","volume":"70","author":"Haiwen","year":"2019","journal-title":"CIESC J.,"},{"key":"10.1016\/j.ejpb.2025.114790_b0185","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1021\/ed300090g","article-title":"Neutralization and acid dissociation of hydrogen carbonate ion: a thermochemical approach","volume":"90","author":"Koga","year":"2013","journal-title":"J. Chem. Educ."},{"key":"10.1016\/j.ejpb.2025.114790_b0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/03639048209052562","article-title":"Evaluations of the mechanism of disintegrant action","volume":"8","author":"Rudnic","year":"1982","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2025.114790_b0195","series-title":"Encyclopedia of Pharmaceutical Technology","first-page":"1037","article-title":"Effervescent pharmaceuticals","author":"Lindberg","year":"2007"},{"key":"10.1016\/j.ejpb.2025.114790_b0200","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1023\/A:1015871406549","article-title":"Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation","volume":"7","author":"Gu","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114790_b0205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2710.2005.00646.x","article-title":"Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays","volume":"30","author":"Arafat","year":"2005","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejpb.2025.114790_b0210","unstructured":"Enalapril Tablets, Sandoz Canada Inc., Product Monograph (2018). https:\/\/pdf.hres.ca\/dpd_pm\/00046861.pdf."},{"key":"10.1016\/j.ejpb.2025.114790_b0215","unstructured":"Renitec Tablets, Organon Pharma UK Limited and MSD Italia S.p.A. facility, Summary of product characteristics (2021). https:\/\/docetp.mpa.se\/LMF\/Renitec%20tablet%20ENG%20SmPC_09001bee807a70d3.pdf."},{"key":"10.1016\/j.ejpb.2025.114790_b0220","unstructured":"Guideline EMA\/CHMP\/338679\/2014, Questions and answers on sodium used as an excipient in medicinal products for human use, 2017, 3-11."},{"key":"10.1016\/j.ejpb.2025.114790_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120993","article-title":"Modulation of biopharmaceutical properties of acidic drugs using cationic counterions: a critical analysis of FDA-approved pharmaceutical salts","volume":"607","author":"Bharate","year":"2021","journal-title":"Int. J. Pharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:15:32Z","timestamp":1753974932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125001675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":45,"alternative-id":["S0939641125001675"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114790","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of ionic excipients on stabilization of enalapril tablets by the formation of alkaline salt \u201cin situ\u201d","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114790"}}